---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic impact on families"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic impact on families. Topics: Informal caregiving hours and effect on caregiver employment in 542 patients in five European countries; Caregiver use and hours of care in a US real-world survey; Caregiver health-related quality of life, productivity, and financial burden in 52 caregivers; Carer utility decrement applied in the NICE appraisal of efgartigimod; 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Chronic inflammatory demyelinating polyneuropathy on Families

<a id="topic-2.2.1.8.3-1"></a>

### Informal caregiving hours and effect on caregiver employment in 542 patients in five European countries

> “In the overall sample, 26.7% of patients required a caregiver, with a mean of 9.1 h of care per week (SD: 24.1).”
> “The partner or spouse was the primary caregiver in 84.3% of cases, and caregiving affected the caregiver’s work and daily activities in 41.4 and 78.9% of cases, respectively.”
> “As shown in Figure 1A , the proportion of patients requiring informal (unpaid) care increased significantly with disability (mild: 7.2%; moderate: 31.2%; severe: 62.9%; p < 0.001).”
> “A work-related impact was reported in 20.0, 35.3, and 52.0% of caregivers for patients with mild, moderate, and severe disability, respectively.”
> “The most reported work-related impacts were reduced working hours (mild: 0.0%; moderate: 26.5%; severe: 20.0%) and cessation of work (mild: 13.3%; moderate: 0.0%; severe: 16%).”

Source: [Brackx et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13368673/)

<a id="topic-2.2.1.8.3-2"></a>

### Caregiver use and hours of care in a US real-world survey

> “The Adelphi CIDP Disease Specific Programme™ is a real-world, cross-sectional survey of US CIDP patients and their neurologists conducted between September 2022 and April 2023.”
> “Nearly a third required caregiver help, usually from a partner/spouse (80%). On average, patients needed 5 hours of care/help per day (n=18).”

Source: [Nowacek et al. (2025)](https://www.mdaconference.org/abstract-library/employment-daily-activities-and-caregiver-burden-in-cidp-results-of-a-real-world-us-survey/)

<a id="topic-2.2.1.8.3-3"></a>

### Caregiver health-related quality of life, productivity, and financial burden in 52 caregivers

> “Most patients and caregivers were from the USA (87.0% and 65.4%, respectively; Table 1 ), whereas the distribution of physicians was more even across the USA, the UK, and Germany”
> “Among caregivers, mean (SD) EQ-5D-3L utility index and EQ-5D VAS scores were 0.79 (0.28) and 76.8 (15.6), respectively.”
> “More than a quarter (28.8%) of the caregivers reported that CIDP affected (quite a bit or very much) their social activities with family and/or friends, while 36.5% reported that CIDP imposed financial burden on themselves and their family.”
> “Among caregivers who were employed, mean (SD) WPAI total productivity impairment pertaining to CIDP was 30.8% (21.0)”

Source: [Yang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396306/)

<a id="topic-2.2.1.8.3-4"></a>

### Carer utility decrement applied in the NICE appraisal of efgartigimod

> “The EAG thought that the company’s EQ-5D-5L data from 21 UK-based carers of people with CIDP in a cross-sectional observational survey of burden on informal carers was more robust. This reported a carer utility of 0.798.”
> “The difference of - 0.0121 between these utility values was used as the carer utility decrement for all carers.”

Source: [NICE ID6409 draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11508/documents/draft-guidance-2)

<a id="topic-2.2.1.8.3-5"></a>

### Caregiver disutility removed from the CDA-AMC reanalysis of efgartigimod

> “No evidence was available on caregiver disutility in the indicated population, and the proxy values used were uncertain given the uncertainty in how health states were defined.”
> “CDA-AMC removed caregiver disutility from the reanalysis.”

Source: [CDA-AMC efgartigimod alfa reimbursement review (2026)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0894r/3193?inline=1)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
